SOURCE: Ingen Technologies, Inc.
RIVERSIDE, CA--(Marketwire - Sep 20, 2012) - Ingen Technologies, Inc. (PINKSHEETS: IGNT), an emerging medical device manufacturer with proprietary medical products for the growing $4 billion respiratory markets, is pleased to announce that Richard Campbell (President of RC Product Development & Engineering), David Holland (CEO of SomaLife Consulting LLC) and Michael Cooper (Executive Vice President of SomaLife Consulting LLC) have joined its Board of Directors as referenced in the 8-K filing on September 12, 2012.
"I am extremely gratified that Richard, David and Michael have joined the Ingen Board," said Gary Tilden, Chairman. "They are proven, dependable leaders in their respective fields, care deeply about product sales and corporate growth issues, and will help assist current management in expanding our corporate presence in the various market sectors we specialize in."
Richard Campbell comes from a long successful executive work history with Johnson & Johnson, Abbott Laboratories and government contract manufacturing. A University of California - Los Angeles graduate in engineering, with other business degrees from the University of Chicago and West Coast University, Mr. Campbell will assist with product growth and government sales for Ingen's product line.
David Holland is the Chief Executive Officer for SomaLife Consulting, LLC, and he brings an impressive background of direct sales knowledge to Ingen. With a successful career and experience at the Executive level, David has been involved in all aspects of corporate strategy and the day-to-day operations of the company, and has been the driving force behind many innovative ideas.
Michael Cooper is the Executive Vice President of SomaLife Consulting, LLC with 20 years of experience in sales and business development. Michael holds a B.A. from the University of Florida and an M.B.A. from Florida International University. Michael will assist with sales & marketing strategies for Ingen.
Ingen's first quarter ended August 31, 2012, and the company, will file its quarterly report before October 15th. During the first quarter Ingen exceeded its goals disclosed in the Plan of Reorganization by placing a national distributor for all of its product sales; a leading distributor of home medical and infusion products which promote recovery and active lifestyles for people with disabilities and those who require non-acute medical care. Further, the company delivered 7,760 Oxyview units to this national distributor. Ingen is currently completing the closing of an acquisition of SomaLife in order to expand its product base on a Global basis, which will infuse the company with additional revenues and assets.
"The worldwide market for respiratory devices had an estimated worth of $4.5 billion in 2010, according to Global Data research, in addition to forecasts predicting a $2.6 billion increase by 2017. This 7% annual growth rate and the arising, continued significant opportunities for our company will only be enhanced by the addition Richard, David and Michael to our board," continued Chairman Gary Tilden. "We continue working to maintain and increase the level of Board quality at Ingen. Our members and shareholders expect a professionally run organization, which ultimately makes a big difference in how we structure our future growth opportunities. The addition of these new Board members is a further step down that path."
FOR MORE UPDATED INFORMATION USE THE FOLLOWING LINK: www.otcfn.com/ignt
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.